Journal
CANCER JOURNAL
Volume 16, Issue 4, Pages 336-341Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e3181eb3879
Keywords
human gene transfer; T-cell receptors (TCRs); chimeric antigen receptors (CARs); tumor regression
Categories
Funding
- Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline
Ask authors/readers for more resources
Building on the principals that the adoptive transfer of T cells can lead to the regression of established tumors in humans, investigators are now further manipulating these cells using genetic engineering. Two decades of human gene transfer experiments have resulted in the translation of laboratory technology into robust clinical applications. The purpose of this review is to give the reader an introduction to the 2 major approaches being developed to redirect effector T-cell specificity. Primary human T cells can be engineered to express exogenous T-cell receptors or chimeric antigen receptors directed against multiple human tumor antigens. Initial clinical trial results have demonstrated that both T-cell receptor-and chimeric antigen receptor-engineered T cells can be administered to cancer patients and mediate tumor regression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available